COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,234 Articles (22,733 medRxiv, 8,501 bioRxiv)

Most recent first Previous |  Page 1044: Articles 10431-10440  | Next

Nucleocapsid 203 mutations enhance SARS-CoV-2 immune evasion
Lin, X., Xue, W., Zhang, Y., Fu, B., Trimpert, J., Xing, N., Kunec, D., Tang, W., Xiao, Y., Meng, K., Shi, S., Wu, H., Meng, G., Zhu, Z.
10.1101/2021.12.20.473471 — Posted: 2021-12-23
Construction of a potent pan-vaccine based on the evolutionary tendency of SARS-CoV-2 spike protein.
Zhao, Y., Ni, W., Liang, S., Dong, L., Xiang, M., Cai, Z., Niu, D., Zhang, Q., Wang, D., Zheng, Y., Zhang, Z., Zhou, D., Guo, W., Pan, Y., Wu, X., Yang, Y., Jing, Z., Jiang, Y., SARS-CoV-2 Vaccine Task Force Group, , Chen, Y., Yan, H., Zhou, Y., Xu, K., Lan, K.
10.1101/2021.12.21.473594 — Posted: 2021-12-23
Anti-SARS-CoV-2 human antibodies retaining neutralizing activity against SARS-CoV-2 B.1.1.529 (omicron)
Imbrechts, M., Kerstens, W., Rasulova, M., Vercruysse, T., Maes, W., Ampofo, L., Ven, K., Lammertyn, J., Vanhoorelbeke, K., Callewaert, N., Neyts, J., Dallmeier, K., Declerck, P., Thibaut, H. J., Geukens, N.
10.1101/2021.12.21.473706 — Posted: 2021-12-23
Structural basis for antibody resistance to SARS-CoV-2 omicron variant
Cerutti, G., Guo, Y., Lihong, L., Zhang, Z., Liu, L., Luo, Y., Huang, Y., Wang, H. H., Ho, D. D., Sheng, Z., Shapiro, L.
10.1101/2021.12.21.473620 — Posted: 2021-12-23
Minimal observed impact of HLA genotype on hospitalization and severity of SARS-CoV-2 infection
Nguyen, A., Yusufali, T., Hollenbach, J., Nellore, A., Thompson, R. F.
10.1101/2021.12.22.21268062 — Posted: 2021-12-22
The Geometry of ATG-Walks of the Omicron SARS CoV-2 Virus RNAs
Kouzaev, G.
10.1101/2021.12.20.473613 — Posted: 2021-12-22
Conjunctival epithelial cells resist productive SARS-CoV-2 infection
Lako, M., Jackson, R. M., Hatton, C. F., Spegarova, J. S., Georgiou, M., Collin, J., Stephenson, E., Vernon, B., Haq, I. J., Hussain, R., Coxhead, J. M., Mudhar, H. S., Wagner, B., Hasoon, M., Davie, T., Rooney, P., Khan, C. M. A., Ward, C., Brodlie, M., Haniffa, M., Hambleton, S., Armstrong, L., Figueiredo, F., Queen, R., Duncan, C. J.
10.1101/2021.12.20.473523 — Posted: 2021-12-22
Neutralization against Omicron SARS-CoV-2 from previous non-Omicron infection
Zou, j., Xia, H., Xie, X., Kurhade, C., Machado, R. R., Weaver, S. C., Ren, P., Shi, P.-Y.
10.1101/2021.12.20.473584 — Posted: 2021-12-22
Virus-like particles (VLPs) are efficient tools for boosting mRNA-induced antibodies
Vogt, A.-C. S., Jörg, L., Martina, B., Krenger, P. S., Chang, X., Zeltins, A., Vogel, M., Mohsen, M. O., Bachmann, M. F.
10.1101/2021.12.20.473421 — Posted: 2021-12-22
Blockade of TMPRSS2-mediated priming of SARS-CoV-2 by the N-terminal peptide of lactoferrin
Ohradanova-Repic, A., Gebetsberger, L., Tajti, G., Ondrovicova, G., Prazenicova, R., Skrabana, R., Barath, P., Stockinger, H., Leksa, V.
10.1101/2021.12.20.473447 — Posted: 2021-12-22

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).